These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 16264901)

  • 1. Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
    Goldman J
    Nat Clin Pract Oncol; 2005 Mar; 2(3):126-7. PubMed ID: 16264901
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Reed SD; Anstrom KJ; Ludmer JA; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2574-83. PubMed ID: 15493042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP).
    Chen Z; Wang C; Xu X; Feng W
    Value Health; 2009; 12 Suppl 3():S85-8. PubMed ID: 20586990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate--a new oral targeted therapy.
    Savage DG; Antman KH
    N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
    [No Abstract]   [Full Text] [Related]  

  • 6. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
    Garside R; Round A; Dalziel K; Stein K; Royle P
    Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH; Ballard EE
    Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
    Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
    Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    Anstrom KJ; Reed SD; Allen AS; Glendenning GA; Schulman KA
    Cancer; 2004 Dec; 101(11):2584-92. PubMed ID: 15493041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
    Groot MT; Ossenkoppele GJ; Kramer MH; van den Boom G; Huijgens PC; Uyl-de Groot CA
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1460-5. PubMed ID: 12908349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia.
    Breitscheidel L
    J Med Econ; 2008; 11(4):571-84. PubMed ID: 19450068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Position paper on imatinib mesylate in chronic myeloid leukaemia.
    O'Brien SG; Rule SA
    Br J Haematol; 2002 Oct; 119(1):268-72. PubMed ID: 12358935
    [No Abstract]   [Full Text] [Related]  

  • 13. Gleevec (STI-571) for chronic myeloid leukemia.
    Med Lett Drugs Ther; 2001 Jun; 43(1106):49-50. PubMed ID: 11402258
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
    Dalziel K; Round A; Garside R; Stein K
    Pharmacoeconomics; 2005; 23(5):515-26. PubMed ID: 15896102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.
    Peggs K; Mackinnon S
    N Engl J Med; 2003 Mar; 348(11):1048-50. PubMed ID: 12637616
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Rajaratnam G; Edwards J
    Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia.
    Gordois A; Scuffham P; Warren E; Ward S
    Br J Cancer; 2003 Aug; 89(4):634-40. PubMed ID: 12915870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer].
    Kodama Y; Kami M
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):577-81. PubMed ID: 20414010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.
    Gratwohl A; Baldomero H; Schwendener A; Gratwohl M; Urbano-Ispizua A; Frauendorfer K
    Leukemia; 2007 Mar; 21(3):383-6. PubMed ID: 17311065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.